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	Abstract 
 
DNA is packaged tightly creating an environment  unconducive to transcriptional 
activation. Chromatin modifications must be made in order to facilitate 
transcription in eukaryotes. Histone deacetylases (HDACs) have become an 
important focus in research due to their role in many fundamental processes 
including differentiation, growth arrest and apoptosis. Previous research has 
shown that HDACs can influence transcription factors and play a crucial role in 
bone homeostasis. This study aims to understand the role of HDAC9 and 
HDAC11 on osteoclast differentiation and activity. While few studies have been 
able to identify HDAC11’s role in osteoclastogenesis, it has been shown in 
previous studies that overexpression of HDAC9 inhibits osteoclast differentiation 
while conversely loss of HDAC9 expression leads to enhanced osteoclastogenesis. 
To investigate the effects of HDACs 9 and 11, I conducted a series of experiments 
and found loss of HDAC9 or HDAC11 expression leads to enhanced osteoclast 
differentiation and elevated bone resorption. 														 ii
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Introduction 
Histone Deacteylase 
Gene expression of eukaryotes begins with the conversion of deoxyribonucleic acid 
(DNA) to ribonucleic acid (RNA) in a process called transcription. One mechanism 
to regulate transcription is to control the accessibility of DNA by winding the DNA 
tightly around proteins or histones. Histones keep the DNA in a condensed form, 
which makes it less accessible to transcription factors. Histone deacetylases 
(HDACs) are enzymes that deacetylate or modify histones and/or other cellular 
proteins to negatively regulate gene expression.  In contrast, histone acetylases 
(HATs) are proteins that acetylate histones, which increases accessibility of the 
DNA for transcription. Acetylation then leads to increased expression of certain 
genes that either promote or inhibit cell differentiation. 
HDACs are divided into two classes based on their protein sequence. Class I 
consists of HDACs 1, 2, 3, and 8. Class I HDACs reside exclusively in the nucleus 
of all cell types and are similar in protein sequence. Early experiments show 
HDACs 1, 2, 3, and 8 are grouped together because they repress transcription 
through their deacetylase activity. Class II consists of HDACs 4, 5, 6, 7, 9, and 10. 
Class II HDACs are located in the cytoplasm as well as the nucleus and are 
expressed in a more restricted tissue pattern indicating they may be involved in cell 
differentiation and development. Class II HDAC’s have also been shown to repress 
transcription, but their mechanism of inhibition is less clear as they have the ability 
to act independently of their deacteylase activity2.  
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Since acetylation plays a key role in the regulation of gene expression, it has 
inspired research to focus on HDACs in relation to the aberrant gene expression. 
HDACs play a role in the maintenance of bone.  Others have shown HDACs can 
regulate osteoblast and chondrocyte differentiation which can be reviewed in 
Bradley, et al.2  The focus of my research is on their regulation of osteoclastic gene 
expression.  
Bone Homeostasis 
Bone is essential for makeup of the human skeleton and undergoes cyclical changes 
of bone formation and bone resorption throughout life. Osteoclasts are key 
regulators in bone homeostasis and function to resorb bone. Bone resorption is 
balanced by osteoblasts which synthesize new mineralized bone. In certain cases, 
the amount of bone resorption does not equal the amount of bone deposition. 
When bone homeostasis is altered, it can manifest in a variety of pathological 
conditions such as osteoporosis. 
Osteoblasts and osteoclasts activity determine whether bone homeostasis is 
maintained. It begins with an osteoclast precursor being recruited to the surface of 
bone, fusing into a multinuclear cell to become a mature osteoclast. Osteoclasts 
form a ruffled border as they contact the bony surface and form a resorptive pit 
referred to as a Howship’s lacunae. In this resorptive pit, osteoclasts secrete 
hydrogen ions creating an acidic environment to resorb the organic bony matrix12. 
After osteoclasts have completed their function, osteoblasts move into the 
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resorptive site and begin to lay down new bone.  It is important to understand that 
there is a third cell involved in bone homeostasis, an osteocyte. Osteocytes are 
terminally differentiated osteoblasts that have become embedded in the bone 
matrix. Recently it was shown that osteocytes express Receptor activator of 
nuclear factor kappa-B ligand (RANKL) and Osteoprotegrin (OPG) to regulate 
osteoclast differentiation19. 
 
 
Figure 1: Bone remodeling showing resorption by osteoclasts, formation by 
osteoblasts, and mineralization by osteocytes. 
www.umich.edu/news/Releases/2005/Feb05/bone.html 
 
 
Osteoclasts 
 
Osteoclasts are multinucleated cells that originate from hematopoietic stem cells. 
Specifically osteoclasts belong to the monocyte/ macrophage lineage and 
eventually differentiate into osteoclast precursor cells with help from macrophage 
colony stimulating factor (M-CSF) and RANKL. M-CSF is a cytokine secreted 
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by osteoblasts and signals the hematopoietic stem cells to differentiate into 
monocytes/osteoclast 
precursors16. Osteoclast precursors exhibit the receptor RANK on its surface. RANK 
 
binds to RANKL expressed on the surface of either osteoblasts or osteocytes 
leading to the osteoclast precursor differentiating into a mature osteoclast. 
 
 
 
 
Figure 2: Osteoclast formation.  J Korean Orthop Assoc. 2009 Apr;44(2):151-158. 
https://synapse.koreamed.org/ViewImage.php?Type=F&aid=421001&id=F1&afn=43_J
KOA_44_2_151&fn=jkoa-44-151-g001_0043JKOA 
 
 
 
RANKL is a member of the tumor necrosis factor (TNF) cytokine family and is 
essential for osteoclastogenesis. It has also been found to be critical for lymph 
node organogenesis, lymphophoiesis, and immune regulation20. Over expression 
of RANKL has been linked to several degenerative bone diseases including 
rheumatoid arthritis and psoriatic arthritis. Mice null for RANKL expression do 
not undergo osteoclastogenesis which manifests as an osteopetrotic phenotype19. 
 
The mechanism by which osteoclast production is inhibited is through binding of 
5		
Osteoprotegrin (OPG) to RANKL. This inhibits RANK-mediated nuclear kappa 
factor B (NF-κB) from being activated. RANK-mediated NF-κB serves as a key 
regulator for osteoclast differentiation. OPG binding to RANKL prevents RANK 
from binding to RANKL and thus inhibits osteoclast precursor cells from further 
differentiating to mature osteoclasts. As a result, excess OPG leads to increased 
bone density and could be a target for future research. This could help further the 
treatment modalities for treating diseases with deficient bone density such as 
osteoporosis. 
 
 
 
 
Figure 3: Detailed schematic diagram with key players in osteoclast formation. Image 
modified from Endocrinol Metab. 2010 Dec;25(4):264-269. English. Published online 
Dec 31, 2010. 
http://eenm.org/search.php?where=aview&id=10.3803/EnM.2010.25.4.264&code=2008
ENM&vmode=PUBREADER#!po=40.9091 
 
 
 
HDACs and Bone 
 
HDACs interact with transcription factors to effect differentiation of osteoblasts and 
osteoclasts. For example, HDACs can inhibit Runx2, a transcription factor that 
when inhibited leads to decreased osteoblast differentiation and mineralization. 
Research is being conducted to find a more definitive answer to how HDACs effect 
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osteoclast differentiation. In 2011, Jensen and Mansky et al. found that in vitro 
loss of HDAC7 accelerated osteoclastogenesis and enhanced osteoclast formation. 
HDAC7 represses the transcription factor MITF, which is necessary for osteoclast 
differentiation. RANKL and 
M-C SF are no longer able to activate the MITF and induce genes necessary for 
osteoclast differentiation10. 
 
HDAC9 is a member of the Class II HDACs due to its protein makeup and 
similarities with HDACs 4, 5 and 7. It has three known splice variants, HDAC 9a/ 
HDAC9b/HDAC9c.  The focus of my study will be on HDAC9c and HDRP.  The 
Mansky lab has determined that only HDAC9c and HDRP are expressed in 
osteoclasts.  HDAC9c or HDRP lacks a catalytic domain necessary for deacetylase 
activity. To remedy this deficiency, HDRP recruits HDAC3, thus allowing it to 
now have deacteylase activity necessary for repression of transcriptional activity6. 
 
A study conducted by Jin, et al. found HDAC9 to be a negative regulator of 
osteoclastogenesis. Deletion of HDAC9 in their study lead to enhanced osteoclast 
differentiation and elevated bone resorption ultimately leading to lower bone mass. 
Osteoclastogenesis can be enhanced by other signaling pathways such as nuclear 
receptor transcription factor PPARγ. Interestingly, HDAC9 is able to inhibit 
PPARγ in synergy with SMRT/NCoR co-repressors. PPARγ, on the other hand, 
can combine with NF-kB and inhibit HDAC9. These interactions are important to 
understand when examining the relationship between HDAC9 and 
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osteoclastogenesis. The authors concluded that the antiosteoclastogenic effect is 
mediated by suppression of HDAC9 and 
PPARγ/RANKL signaling.  In the absence of RANKL, HDAC9 impedes PPARγ’s 
ability to function6.  However, the study by Jin et al. did not determine which 
isoform of HDAC9 was disrupted in their mouse model.    
 
A review of the literature provides little information is known about HDAC11. A 
study published by Gao et al. in 2002 described HDAC11 as a novel and unique 
member of the histone deacetylase family that may have distinct physiologic roles 
from other known HDACs. Sequence analysis of HDAC11 protein shows that it 
contains conservative residues at the catalytic core regions shared by both Class I 
and II HDACs5. HDAC11 was found in the study to be the smallest member in the 
family and the most closely related to HDAC3 and HDAC8, which suggests it may 
be more closely related to class I than class II HDACs. However, the classification 
of HDAC11 has yet to be determined. While epitope tagged HDAC11 protein 
localizes primarily to the nucleus (similar to Class I), it also may be present in 
protein complexes that contain HDAC6 in the cytoplasm according to co-
immunoprecipitation experiments by the same authors5. 
Previous studies have shown that HDAC6 decreases adhesion of osteoclasts through its 
 
ability to deacetylate microtubules4. Further experiments need to be done to help 
clarify HDAC11’s role in osteoclastogenesis. 
 
 
HDAC Inhibitors 
 
Currently, HDAC inhibitors are used to treat epilepsy and certain cancers7,8,9. FDA 
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approved Valproate is a medication used to treat certain cancers, but also has been 
shown with long term use to decrease bone mineral density in humans1,18. Other in 
vitro studies have shown HDAC inhibitors such as Trichostatin A (TSA) can 
suppress osteoclast differentiation and enhance osteoblast differentiation13,14. TSA 
and sodium butyrate are considered broad spectrum HDAC inhibitors which can 
inhibit all Class I and Class II HDACs10. 
 
Osteoclasts in Orthodontics 
 
Orthodontic forces alter the bone homeostasis and induce remodeling. Osteoblast 
and osteoclast activity determine the fate of bone as orthodontists move teeth within 
the mandible and maxilla. Chemical messengers lead to remodeling of alveolar 
bone and tooth movement. Studies have demonstrated increases in the 
concentrations of RANKL and OPG during orthodontic tooth movement, which 
suggests that stress created by applying an orthodontic force may induce the 
formation of osteoclasts through up regulation of RANKL11.  Tooth movement 
typically begins two days after orthodontic forces are initiated beginning as 
osteoblasts and osteoclasts remodel the bony socket. 
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Figure 4: Osteoclasts are formed to remove bone on the right side (compression 
side). Osteoblasts are formed to add new bone and remodel resorbed areas on the 
left side (tension side). The tooth is the diagram has orthodontic forces moving it to 
the right as indicated by the arrow. http://omnidentalgroup-
austin.blogspot.com/2014/08/drinking-coffee-accelerates-orthodontic.html 
 
 
HDACs could prove be clinically significant to the field of orthodontics as well as 
many other fields that deal with treatment or manipulation of bony structures. 
These experiments will help to enhance our understanding of HDAC11 and 
HDAC9, and hopefully contribute to a larger goal of understanding how HDACs 
can regulate osteoclast differentiation, skeletal formation, and the field of 
orthodontics. 
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Hypotheses 
 
1. My first hypothesis is that expression of HDAC9 inhibits osteoclast 
differentiation. I expect that knockdown of HDAC9 will increase 
osteoclastogensis.  I expected both an increase in size as well as increased 
resorption compared to the control. 
2. My second hypothesis is that HDAC11 also inhibits osteoclast 
differentiation. For this hypothesis to be correct, I expect that knockdown 
of HDAC11 will increase osteoclastogenesis. This would produce increased 
size of osteoclasts after TRAP stain and increased areas of resorption on the 
calcium phosphate resorption plates compared to the control. 
 
 
Specific Aims 
 
The specific aims of this study are to determine whether reduced expression of 
HDAC9 and HDAC11 affect osteoclast differentiation and activity. This will be 
done by infecting osteoclasts with lentiviruses expressing shRNAs targeting HDAC9 
or HDAC11. 
Analysis will be done to evaluate the size and number of osteoclasts after fixing the 
cells and performing a TRAP stain. Further analysis will be conducted to observe 
the pit number, average pit size, and percent area resorbed on the calcium phosphate 
resorption plates. 
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Materials and Methods 
 
Harvesting bone marrow and osteoclasts 
 
Bone marrow macrophages were harvested from the femurs and tibiae of wild type 
mice. The ends of the bones were cut and the marrow flushed. Red blood cells were 
lysed from the bone marrow tissue with red blood cell lysis buffer, and the 
remaining cells plated on 100mM plates and cultured overnight in osteoclast media 
(phenol red-free alpha-MEM (Gibco) with 5% heat-inactivated fetal bovine serum 
(Hyclone), 25 unites/mL penicillin/ streptomycin (Invitrogen), 400 mM L-
Glutamine (Invitrogen), and supplemented with 0.1% CMG 14-12 conditioned 
media containing M-CSF).  The non-adherent cell population, including osteoclast 
precursor cells, were then separated and re-plated at approximately 100,000 cells 
per well in the presence of 0.1% CMG 14-12.  After 48 hours plated cells are 
stimulated with M-CSF and RANKL to begin osteoclast differentiation.  From this 
point on, the cells in culture are osteoclasts.  Two dishes with 24 wells were used 
in each round of the experiment. One dish was used for TRAP staining and the 
other, a calcium phosphate coated plate, to analyze demineralization. 
 
 
Lentiviral Transfection 
 
Lentiviral vectors were used encoding shRNAs against HDAC9 or HDAC11 or a 
control shRNA. Lentiviral vectors were used to produce replication defective 
lentiviruses according to the manufacturer’s protocols. Twenty-four hours after 
plating, lentivirus was added to the osteoclasts at 37°C in the presence of 0.1% 
CMG 14-12 conditioned media. Two distinct lentiviruses were used in this study: 
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each virus was added to 3 wells on each plate. Lentivirus numbered 029 (shRNA 
#1) and 224 (shRNA #2) express an shRNA against HDAC11. Lentivirus 
numbered 592 (shRNA #1) and 594 (shRNA #2) express a shRNA against 
HDAC9. We verified that the shRNA knocked down expression of HDAC11 or 
HDAC9 (confirmed by qPCR). The same pattern for addition of virus was used in 
each round of experiment. A control virus that expresses a scrambled shRNA that 
should not affect expression of any HDAC was added to 3 wells to demonstrate the 
effect of virus infection on the osteoclasts. The next day lentivirus was removed 
from the wells and cells were fed with 0.1% CMG 14-12 conditioned media and 
RANKL. Cells were fed every other day with RANKL and 0.1% CMG 14-12 
conditioned media. After 5 days, the cells were fixed with 4% paraformaldehyde. 
 
 
TRAP Stain 
 
The fixed cells were stained for tartrate resistant acid phosphatase (TRAP) 
expression with tartrate (5 mg), Napthol AS-MX phosphate, 0.5 mL M, M-
Dimethyl formamide 50 mL acetic acid buffer (1 mL acetic acid, 6.8 g sodium 
acetate trihydrate, 11.5 g 
sodium tartrate in 1 L water), and 25 mg Fast Violet LB salt. The cells were 
incubated for approximately 20 minutes and then images were captured with light 
microscopy on the 4x objective. Images had to be converted into binary format on 
NIH Image J for measurements of size and number to be recorded. 
 
 
Resorption Plates 
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Bone marrow macrophages (BMMs) were plated on OsteoAssay plates (Corning) 
in 0.1% CMG 14-12 conditioned media for 2 days. After 2 days BMMs were 
given 0.1% CMG 14-12 conditioned media and RANKL to stimulate 
differentiation. Once cells had differentiated into multinuclear osteoclasts the 
media was aspirated and 100 uL of 10% bleach was added to each well and 
incubated at room temperature for 5 minutes.  Resorption occurred for 5 days.  The 
wells were then washed twice with H2O, allowed to air-dry. Images were captured 
with light microscopy on 4x objective. Images needed to be converted into binary 
format on NIH Image J for measurements of size, number, and percent of area 
resorbed to be recorded. 
 
 
Statistical Analysis 
 
All experiments were run at least three times. Results show the mean ± standard 
deviation. ANOVA analysis followed by a Tukey’s multiple comparison test was 
used to compare data utilizing the computer program Prism version 5. 
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Results 
 
Knockdown of HDAC9 Expression Enhances Osteoclast Differentiation 
 
The study conducted by Jin et al. concluded that the class II HDAC9 is a 
physiologically relevant modulator of bone remodeling and skeletal homeostasis. 
Their study found HDAC9 controls bone turnover by suppressing osteoclast 
differentiation and bone resorption6. Our present study attempts to further 
investigate the role of HDAC9 in osteoclast differentiation and activity by 
infecting wild type mouse cells with two different viruses expressing a shRNA 
against HDAC9 or a control shRNA virus. 
Cultures were given RANKL until multicellular osteoclasts appeared. Cells were 
fixed and TRAP stained. Both HDAC9 shRNA infected cells showed a significant 
decrease in number of multicellular osteoclasts compared to the control infected 
cells. The average number of osteoclasts was found to be 312 for the control 
group, 225 for shRNA #1, and 25 for shRNA#2. The average size of the 
osteoclasts increased in the HDAC9 shRNA infected cells compared to the control. 
The average size of the osteoclasts was 0.004 
mm2 for the control, 0.007 mm2 for shRNA #1, and 0.006 mm2 for shRNA #2. 
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Figure 4. Knockdown of HDAC9 increases osteoclast differentiation. (A). 
Representative images of TRAP stained osteoclasts. Quantification of (B) Number 
of TRAP positive cells containing three or more nuclei (C) Size of TRAP positive 
cells containing three or more nuclei. *** denotes p ≤ 0.001, * denotes p ≤ 0.05. 
 
Osteoclasts with decreased HDAC9 Expression have increased activity 
 
Wild type bone marrow macrophages were infected with either a HDAC9 shRNA or 
control shRNA virus (as described above) and plated on calcium phosphate coated 
plates. We examined pit number, average pit size, and total percent area resorbed. 
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Figure 5. Knockdown of HDAC 9 increases resorption. (A) Representative 
images of calcium phosphate coated wells. Quantification of (B) pit number, (C) 
average pit size, 
(D) percent area resorbed. ns denotes no statistical significance, * denotes p<.05, 
*** denotes p ≤ 0.001. 
 
 
Pit number for HDAC 9 shRNA #1 was 150 compared to 124 for control while pit 
number for HDAC9 shRNA #2 was 138. Neither were statistically significant. 
The average pit size was .002 mm2 for the control and .003 mm2 for shRNA #1 
and for shRNA #2. The average percent area resorbed for the control was 3.9% for 
the control, 6.1% for shRNA #1, and 5.7% for shRNA #2. 
 
 
 
Graph demonstrating knock down in expression of HDAC9 
 
Osteoclast precursors from WT mice were infected with either a lentivirus expressing a 
scrambled (control) shRNA or lentiviruses expressing two distinct shRNAs targeting 
HDAC9.    Real time PCR was used to measure HDAC9 expression 48 hours after 
infection by the lentivirus.  I detected a significant reduction in HDAC9 in the shRNA-
infected cells compared to the control-infected cells. 
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Osteoclasts with reduced HDAC11 expression are enhanced in differentiation 
 
The study by Gau et al. determined HDAC11 is a unique deacetylase displaying 
characteristics from Class I and Class II HDAC family members. Their study found 
HDAC11 resides predominantly in the nucleus, a characteristic shared by Class I 
HDACs. However, HDAC11 mRNA is found in specific tissues and may be 
present on protein complexes containing HDAC6, a known Class II HDAC. Our 
study attempted to gain more understanding of HDAC11’s role in osteoclast 
differentiation and activity. We infected wild type bone marrow macrophages with 
either a shRNA targeting HDAC11 or a control shRNA. Cultures were given 
RANKL until multicellular osteoclasts appeared. Cells were fixed and TRAP 
stained. The HDAC11 shRNA infected cells showed a decrease in the number of 
osteoclasts when compared to the control (although not statistically significant). 
The average number of osteoclasts was found to be 315 for the control group, 277 
for shRNA #1, and 268 for shRNA#2. The average size of the 
osteoclasts was 0.003 mm2 for the control, 0.0065 mm2 for HDAC11 shRNA #1, and 
0.007 mm2 for HDAC11 shRNA #2. 
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Figure 6. Knockdown of HDAC11 increases osteoclast differentiation. (A). 
Representative TRAP stained images of osteoclasts. Quantification of (B) Number 
of TRAP positive cells containing three or more nuclei (C) Size of TRAP positive 
cells containing three or more nuclei. ns denotes no statistical significance, * 
denotes p ≤ 0.05. 
 
 
Osteoclasts with reduced expression of HDAC 11 shRNA have increased activity 
 
Bone marrow macrophages were infected with either a HDAC11 shRNA or a 
control shRNA and plated on calcium phosphate coated plates. We examined pit 
number, average pit size, and total percent area resorbed. 
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Figure 7. Knockdown of HDAC11 increases resorption. (A) Representative 
images of calcium phosphate coated wells. Quantification of (B) pit number, (C) 
average pit size, 
(D) percent area resorbed. ns denotes no statistical significance, * denotes 
p<.05, *** denotes p ≤ 0.001. 
 
The pit number was 47.38 for the control, 90.15 for HDAC 11 shRNA #1 and 
159.23 for HDAC11 shRNA #2. The average pit size was 0.002 mm2 for the 
control, 0.002 mm2 for shRNA #1, and 0.003 mm2 for shRNA #2. The average 
percent area resorbed for the control was 1.25%, 2.87% for shRNA #1, and 7.21% 
for shRNA #2. 		
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Graph demonstrating knock down in expression of  HDAC11 
 
Osteoclast precursors from WT mice were infected with either a lentivirus expressing a 
scrambled (control) shRNA or lentiviruses expressing two distinct shRNAs targeting 
HDAC11.    Real time PCR was used to measure HDAC11 expression 48 hours after 
infection by the lentivirus.  I detected a significant reduction in HDAC11 in the shRNA-
infected cells compared to the control-infected cells. 
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Discussion 
 
A previous review of the HDAC family by de Ruijter el al. found HDACs to be key 
enzymes in the regulation of gene expression. Inhibition of HDACs can lead to a 
variety of processes including apoptosis, necrosis, differentiation, inhibition of 
proliferation and cytostasis4. Our study examined the effect of inhibiting HDAC9 
and HDAC11 on osteoclast differentiation and activity. 
 
Our results showed that when shRNAs were used to knockdown HDAC9, 
osteoclasts decreased in number by approximately 1.2-1.4 fold and increased in 
size by 1.2-1.5 fold. The increase in size is due to increased osteoclast fusion as 
evidenced by decrease in the number of TRAP positive multinuclear cells. 
Osteoclasts with decreased HDAC9 expression have increased activity manifested 
as a 1.5 fold increase in percent area resorbed when treated with HDAC9 shRNA. 
These findings agree with the previous study by Jin et al. that found decreased 
HDAC9 expression leads to increased osteoclast differentiation and increased 
bone resorption. Jin et al. demonstrated that the antiosteoclastogenic effect of 
HDAC9 is mediated by suppression of the PPARγ/RANK signaling pathway. 
There are two forms of HDAC9: one full length HDAC9 and one 
HDRP which lacks the catalytic domain4. The study by Jin et al. did not 
demonstrate 
 
which forms of HDAC9 are inhibitors of osteoclast differentiation. While both 
forms are known to be expressed in osteoclasts, no study has distinguished 
between the two forms. HDAC11 shRNA infected osteoclasts demonstrated a 
decrease in osteoclast number (though not statistically significant). The osteoclasts 
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did show a statistically significant increase in osteoclast size compared to the 
control. This is the first study to demonstrate the role of HDAC11 in regulating 
osteoclast differentiation and activity. HDAC11 is a unique HDAC that shares 
characteristics common with both class I and II.  The Mansky lab has preliminary 
data demonstrating that expression of HDAC11 was highest at day 2- 3 which may 
indicate a role in osteoclast fusion since fusion of osteoclast precursors occurs at 
days 2-3. Other studies were able to show expression of HDAC11 in other cells 
such as the kidney, heart, brain, skeletal muscle, and testis5. This suggests that 
although HDAC11’s function is unknown at this time, its function may be tissue 
specific. Future studies will help us understand the transcription factors in 
osteoclasts that interact with HDAC11, where HDAC11 is expressed (nucleus 
and/or cytoplasm), and if there is a shuttling function associated with HDAC11. 
 
Previous work from the Mansky lab demonstrated that suppression of HDAC7, a class IIa 
HDAC, promoted osteoclastogenesis and increased osteoclast size, indicating HDAC7 is 
a repressor of OCL differentiation. Interestingly, suppression of HDAC3, a class I 
HDAC, had the opposite effect of HDAC7 suppression, leading to reduced osteoclast 
number and size.  Additionally, another class IIa HDAC, HDAC9, has also been shown 
to represses osteoclast differentiation through a mechanism distinct from HDAC7’s role 
in OCL differentiation, indicating that the remaining class II HDACs may also play 
separate and pivotal roles in osteoclastogenesis.  
 
The field of orthodontics applies forces to teeth in order to move them within bone. Once 
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force is applied, fluid is expressed from the periodontal ligament (pdl) causing the tooth 
to displace within the pdl space compressing the ligament in some areas and stretching it 
in others. During this time, there is an increase in RANKL and osteoprotegrin (OPG) in 
the gingival crevicular fluid surrounding teeth. This suggests the pdl cells under stress 
induce formation of osteoclasts via upregulation of RANKL11. Advances in technology 
have lead to several new methods geared toward shortening treatment time by 
accelerating orthodontic tooth movement. Orthodontists may look to bone biologists for 
answers in the future about the use of HDACs to impact the bone remodeling process. 
 
This study is able to conclude that osteoclasts with reduced HDAC9 expression are 
enhanced in differentiation and have increased activity. Additionally, osteoclasts 
with reduced HDAC11 expression are enhanced in differentiation and have 
increased activity.  Further research will help us better understand the mechanism 
by which HDAC9 and HDAC11 inhibit osteoclast differentiation.  Our experiments 
used cultured cells in vitro and are thus not able to definitively state HDAC 9 and 
11’s role in osteoclast differentiation and activity.  It has already been shown by 
others that loss of HDAC9 in a mouse model leads to enhanced osteoclast 
differentiation; however, neither my study nor the animal model was able to 
determine if HDRP or HDAC9 is the critical protein necessary in regulating 
osteoclast differentiation.  To conclusively determine HDAC 11’s role, it would 
require engineering a mouse species null for HDAC 11 expression in 
osteoclasts.  Experiments are still ongoing in the Mansky lab to help us answer 
these questions. 
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